Ipilimumab
- Generic Name
- Ipilimumab
- Brand Names
- Yervoy
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 477202-00-9
- Unique Ingredient Identifier
- 6T8C155666
- Background
Ipilimumab is a fully humanized IgG1 monoclonal antibody that blocks cytotoxic T lymphocyte antigen-4 (CTLA-4). Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes. Ipilimumab was developed by Bristol-Myers Squibb and Medarex.
Ipilimumab was granted FDA approval on 25 March 2011.
- Indication
Ipilimumab is indicated in the following cancerous conditions:
Melanoma
Renal Cell Carcinoma (RCC)
Colorectal Cancer
Hepatocellular Carcinoma
Non-Small Cell Lung Cancer (NSCLC)
Malignant Pleural Mesothelioma
Esophageal Cancer
...
- Associated Conditions
- Cutaneous Melanoma, Hepatocellular Carcinoma, Metastatic Esophageal Squamous Cell Carcinoma, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Microsatellite Instability High Metastatic Colorectal Cancer (CRC), Mismatch Repair-deficient (dMMR) Metastatic Colorectal Cancer (CRC), Recurrent Non-small Cell Lung Cancer, Unresectable Melanoma, Poor or intermediate risk Advanced Renal Cell Carcinoma (aRCC), Unresectable Malignant Pleural Mesothelioma (MPM), Unresectable, advanced Esophageal Squamous Cell Carcinoma (ESCC)
- Associated Therapies
- First Line Chemotherapy
Study of Nivolumab (BMS-936558) Plus Ipilimumab Compared With Ipilimumab Alone in the Treatment of Previously Untreated, Unresectable, or Metastatic Melanoma
- Conditions
- Interventions
- First Posted Date
- 2013-08-22
- Last Posted Date
- 2022-03-18
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 142
- Registration Number
- NCT01927419
- Locations
- 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States
Lenalidomide and Ipilimumab After Stem Cell Transplant in Treating Patients With Hematologic or Lymphoid Malignancies
- First Posted Date
- 2013-08-09
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 41
- Registration Number
- NCT01919619
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Study of the Drug Ipilimumab for Metastatic Merkel Cell Carcinoma
- Conditions
- First Posted Date
- 2013-08-01
- Last Posted Date
- 2019-12-17
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT01913691
Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2013-07-11
- Last Posted Date
- 2024-11-12
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 146
- Registration Number
- NCT01896999
- Locations
- 🇺🇸
Anchorage Oncology Centre, Anchorage, Alaska, United States
🇺🇸Katmai Oncology Group, Anchorage, Alaska, United States
🇺🇸Providence Alaska Medical Center, Anchorage, Alaska, United States
FOLFIRINOX Followed by Ipilimumab With Pancreatic Tumor Vaccine in Treatment of Metastatic Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2013-07-11
- Last Posted Date
- 2020-05-19
- Target Recruit Count
- 83
- Registration Number
- NCT01896869
- Locations
- 🇺🇸
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
🇺🇸The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
🇺🇸Washington University School of Medicine, Saint Louis, Missouri, United States
HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma
- Conditions
- Interventions
- First Posted Date
- 2013-05-17
- Last Posted Date
- 2023-12-05
- Lead Sponsor
- Clinigen, Inc.
- Target Recruit Count
- 29
- Registration Number
- NCT01856023
- Locations
- 🇺🇸
Moores UCSD Cancer Center, La Jolla, California, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Columbia University Medical Center, Herbert Irving Comprehensive Cancer Center, New York, New York, United States
Phase I Study of Intralesional Bacillus Calmette-Guerin (BCG) Followed by Ipilimumab in Advanced Metastatic Melanoma
- Conditions
- Interventions
- First Posted Date
- 2013-04-23
- Last Posted Date
- 2022-10-12
- Lead Sponsor
- Ludwig Institute for Cancer Research
- Target Recruit Count
- 5
- Registration Number
- NCT01838200
- Locations
- 🇦🇺
Austin Health, LICR Melbourne Austin Branch, Heidelberg, Victoria, Australia
Sipuleucel-T and Ipilimumab for Advanced Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2013-04-16
- Last Posted Date
- 2017-08-24
- Lead Sponsor
- Prostate Oncology Specialists, Inc.
- Target Recruit Count
- 9
- Registration Number
- NCT01832870
- Locations
- 🇺🇸
Prostate Oncology Specialists, Inc., Marina del Rey, California, United States
Phase II Study of Abraxane Plus Ipilimumab in Patients With Metastatic Melanoma
- First Posted Date
- 2013-04-09
- Last Posted Date
- 2022-02-08
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 21
- Registration Number
- NCT01827111
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Evaluation of Circulating T Cells and Tumor Infiltrating Lymphocytes (TILs) During / After Pre-Surgery Chemotherapy in Non-Small Cell Lung Cancer (NSCLC)
- Conditions
- Interventions
- First Posted Date
- 2013-03-29
- Last Posted Date
- 2021-02-26
- Lead Sponsor
- Duke University
- Target Recruit Count
- 24
- Registration Number
- NCT01820754
- Locations
- 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.